Dr. Minoo Battiwalla

Dr. Battiwalla directs Blood Cancer Outcomes Research across the Sarah Cannon Transplant & Cellular Therapy Network and practices at TriStar Centennial Medical Center in Nashville. Every new patient undergoes high-sensitivity measurable-residual-disease testing, broad next-generation sequencing, and pharmacogenomic screening; these data feed weekly molecular conferences where transplant, cellular-therapy, and supportive-care experts align conditioning intensity, graft source, and investigational options to each disease biology.

 

His translational portfolio has shaped contemporary practice. NIH-funded studies defined late cardiovascular and endocrine toxicities after allogeneic transplant and guided the NIH Late Effects Consensus still used worldwide. He later led multicentre analyses that validated outpatient CAR T-cell administration and documented comparable cytokine-release-syndrome control to inpatient care, a result now incorporated in Sarah Cannon protocols.

 

Education and equity frame his clinical mission. Dr. Battiwalla mentors fellows through the International CML Foundation “CURE” programme and co-designs bilingual survivorship workshops that pair graft-versus-host self-management with tele-monitoring, lowering unplanned readmissions across fifteen network centres. His outcomes-research unit mines linked electronic-health-record and registry data to benchmark transplant quality and accelerate learning across the United States and the United Kingdom.